Ezetimibe - Pharmacokinetics and therapeutics;Ezetimiba - Farmacocinética e terapêutica

Arquivos Brasileiros de Cardiologia

Volumn 85, Issue SUPPL. 5, 2005, Pages 20-24

  Araújo, Renata G ^a   Casella Filho, Antonio ^a   Chagas, Antonio Carlos P ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Ezetimibe; Metabolism; Statin

Indexed keywords

CARRIER PROTEIN; COLESTIPOL; DRUG METABOLITE; EZETIMIBE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; CLINICAL TRIAL; DRUG ABSORPTION; DRUG EFFECT; DRUG ELIMINATION; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; DRUG TRANSPORT; FECES; HUMAN; HYPERCHOLESTEROLEMIA; INTESTINE CELL; LIPID ABSORPTION; NONHUMAN; REVIEW;

EID: 31144460863     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: 10.1590/S0066-782X2005002400006     Document Type: Review

References (53)

1. Castelli WP,Garrison RJ,Wilson WF, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham study. 1986;256 (120):2835-8
2. Cullen P. Evidence that tryglicerides are an independent coronary risk factor. Am J Cardiol 2000;86:943-9
3. Després JP,lemieux I, Daganais GR, et al.HDL-chooesterol as a marker of coronary heart disease risk: the Québec cardiovascular study. Atherosclerosis 2000; 153: 263-72
4. Ballantyne C, Olsson AG, Cook TJ, Mercuri M, Pedersen T, Kjekshus J. For the Scandinavian Simvastatin Survival Study (4S) Group. Influence of low high-density lipoprotein cholesterol and elevated triglycerides in coronary heart disease events and response to simvastatin therapy in 4S. Circulation 2001;104:3046-3051.
5. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary artery disease. Lancet 1994; 344: 1383-9
6. Pedersen TR, Wilhelmsen L, Faergeman O, et al. Follow-up study of patients randomized in the Scandinavian Simvastatin Survival Study (4S) of cholesterol lowering.Am J Cardiol 2000; 86: 257-62
7. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of cholesterol levels. N Engl J Med 1998; 339: 1349-57
8. The LIPID Study Group: Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet 2002; 359: 1379-87
9. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20.536 high-risk individuals a randomized placebo controlled trial. Lancet 2002; 360: 7-22
10. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, Crowe T, Howard G, Cooper CJ, Brodie B, et al; REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291:1071-1080
11. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol. 1998;81:582-587
12. C. J. Vaughan and A. M. Gotto Jr. Update on Statins: 2003. Circulation,. 2004; 110(7): 886-892
13. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG; PROSPER study group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. PROspective Study of Pravastatin in the Elderly at Risk. Lancet. 2002;360:1623-1630.
14. III Diretrizes Brasileiras sobre Dislipidemias e Diretrizes de Prevenção da Aterosclerose da Sociedade Brasileira de Cardiologia. Arq. Bras. Cardiol. 2001; 77 (supl III): 1- 48
15. Grundy S.M; Cleeman J.I.; Merz C.N.B.; Brewer H.B; Clark L.T.; Hunninghake D.B.; Pasternak R.C.; Smith S.C.; Stone N.J; for the Coordinating Committee of the National Cholesterol Education Program, Endorsed by the National Heart, Lung, and Blood Institute, American College of Cardiology Foundation, and American Heart Association. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004; 110: 227-239.
16. Bruckert E, Giral P, Tellier P. Perspectives in Cholesterol-Lowering Therapy: The Role of Ezetimibe, a New Selective Inhibitor of Intestinal Cholesterol Absorption. Circulation. 2003; 107: 3124-3128.
17. EUROASPIRE II Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: principal results from EUROASPIRE II. Eur Heart J. 2001; 22: 554-572.
18. Frolkis JP, Pearce GL, Nambi V, et al. Statins do no meet expectations for lowering lipoprotein cholesterol levels when used in clinical practice. Am J Med. 2002; 113: 625-629.
19. Linton MF, Fazio S, Macrophages, inflammation, and atherosclerosis. Inter J Obesity (2003) 27, S35-S40.
20. Bays H; Stein EA. Pharmacotherapy for dyslipidaemia - current therapies and future agents. Expert Opinion on Pharmacotherapy 2003, vol. 4, no. 11, pp. 1901 - 1938
21. Vicent FM; Tuckerman E.C. Ezetimibe for Management of Hypercholesterolemia. Ann Pharmacother. 2003;37:839-48
22. Llaverias G, Laguna JC, Alegret M Pharmacology of the ACAT inhibitor avasimibe (CI-1011). Cardiovasc Drug Rev. 2003 Spring;21(1):33-50.
23. Burnett, D.A.; Caplen, M.A.; Davis, HR. 2-Azetidinones as Inhibitors of Cholesterol Absorption.J. Med. Chem. 1994, 37, 1733-1736.
24. Van Heek M, France CF, Compton DS, et al.In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461. J Pharmacol Exp Ther 1997; 283: 157-63
25. Van Heek M, Farley C, Compton DS, et al. Comparision of the activity and disposition of the novel cholesterol absortion inhibitor, SCH58235, and its glucoronide, SCH60663. Br J Pharmacol 2000; 129:1748-54
26. Punwani N, Pai S, Bach C, et al. Effect of food on oral bioavailability of SCH 58235 in healthy male volunteers. AAPS Annual Meeting.1998; San Francisco (CA), AAPS Annual Meeting Supplement (1): 486
27. Zhu Y, Statkevich P, Kosoglou T, et al. Effect of age on the pharmacokinetics of ezetimibe. American Association of Pharmaceutical Scientists (AAPS) PharmSci Suppl 2000; 2 (2): 2082
28. Patrick JE, Kosoglou T, Stauber KL, Alton KB, Maxwell SE, Zhu Y, et al. Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects. Drug Metab Dispos 2002;30:430-7
29. Ezzet F, Krishna G, Wexler DB, et al. A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe. Clin Ther 2001; 23 (6): 871-85
30. Reyderman L, Kosoglou T, Statkevich P, et al. Pharmacokinetics of ezetimibe in subjects with normal renal function or severe chronic renal insufficiency . Clin Pharmacol Ther 2002 ; 71: P27
31. Zhu Y, Statkevich P, Kosoglou T, et al. Effect of SCH 58235 on the activity of drug metabolizing enzymes in vivo. Clin Pharmacol Ther 2000; 67: 152
32. Van Heek M, Farley C, Compton DS, et al. Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function. Br J Pharmacol 2001; 134 (2): 409-17
33. Keung ACF, Kosoglou T, Statkevich P, et al. Ezetimibe does not affect the pharmacokinetics of oral contraceptives. Clin Pharmacol Ther 2001; 69: P55
34. Bauer KS, Kosoglou T, Statkevich P, et al. Ezetimibe does not affect the pharmacokinetics or pharmacodynamics of warfarin. Clin Pharmacol Ther 2001; 69: P5
35. Statkevich P, Reyderman L, Kosoglou T, et al. Ezetimibe does not affect the pharmacokinetics and pharmacodynamics of glipizide. Clin Pharmacol Ther 2001; 69: P67
36. Dujovne CA, Ettinger MP, McNeer JF, et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 2002; 90:1092-1097
37. Bays HE, Moore PB, Drehobl MA, et al. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin Ther 2001; 23 (8): 1209-30
38. Stein E. Results of phase I/II clinical trials with ezetimibe, a novel selective cholesterol absorption inhibitor. Eur Heart J Suppl 2001; 3 Suppl. E: E11-6
39. Jurado J, MD, Richard Seip, PhD, and Paul D. Thompson, MD. Effectiveness of Ezetimibe in Clinical Practice. Am J Cardiol 2004;93:641-643
40. Knopp RH, Gitter H, Truitt T, et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 2003; 24:729-741
41. .Ziajka PE, Reis M, Kreul S, King H. Initial Low-Density Lipoprotein Response to Statin Therapy Predicts Subsequent Low-Density Lipoprotein Response to the Addition of Ezetimibe. Am J Cardiol 2004;93:779-780
42. O'Neill F, Patel D, Knight B, et al. Determinants of variable response to statin treatment in patients with refractory familial hypercholesterolemia. Arterioscler ThrombVasc Biol 2001;21:832-837
43. Melani L, Mills R, Hassman D, et al. Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: A prospective, randomized, double-blind trial. Eur Heart J 2003; 24:717-728.
44. Kerzner B, Corbelli J, Sharp S, et al. Efficacy and safety of ezetimibe coadministered with lovastatin in patients with primary hypercholesterolemia. Am J Cardiol 2003; 91:418-424.
45. Ballantyne CM, Houri J, Notarbartolo A, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia. Circulation 2003; 107:2409-2415
46. Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002; 40:2125-2134.
47. Cannon CP. EASE TRIAL. The American College of Cardiology Annual Scientific Session 2004 in New Orleans, Louisiana
48. Simons L, Melvin Tonkon, Luis Masana, Darbie Maccubbin, Arvind Shah, Michael Lee and Barry Gumbiner. Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome .CUR MED RES OPIN. 2004; 20(9): 1437-1445
49. Davis HR Jr, Compton DS, Hoos L, Tetzloff G. Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in ApoE knockout mice. Arterioscler Thromb Vasc Biol. 2001 Dec;21(12):2032-8.
50. Davidson MH, Dillon MA, Gordon B, et al.Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med 1999;159:1893-900
51. Xydakis AM, Guyton JR, Chiou P, et al. Effectiveness and Tolerability of Ezetimibe Add-on Therapy to a Bile Acid Resin-Based Regimen for Hypercholesterolemia. Am J Cardiol. 2004;94:795-797.
52. Kosoglou T, Statkevich P, Fruchart JC, Pember LJ, Reyderman L, Cutler DL, Guillaume M, Maxwell SE, Veltri EP. Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe.Curr Med Res Opin. 2004 Aug;20(8):1197-207.
53. Reyderman L, Kosoglou T, Statkevich P, Pember L, Boutros T, Maxwell SE, Affrime M, Batra .Assessment of a multiple-dose drug interaction between ezetimibe, a novel selective cholesterol absorption inhibitor and gemfibrozil.Int J Clin Pharmacol Ther. 2004 Sep;42(9):512-8.